Proposal to list a range of Interventional Cardiology products supplied by Boston Scientific NZ Limited

Hospital devices

Consultation Closed

PHARMAC is seeking feedback on a proposal to list a range of Interventional Cardiology products supplied by Boston Scientific NZ Limited (“Boston”) in Part III of Section H of the Pharmaceutical Schedule from 1 April 2016. The proposal is subject to approval by the PHARMAC Board or its delegate following this consultation.

In summary, this proposal would result in 1016 interventional cardiology products which are already supplied to DHB Hospitals, being supplied under a proposed national agreement with Boston, that all DHBs may purchase under. This agreement is not a sole supply agreement, and DHBs may continue to purchase other suppliers’ brands of interventional cardiology products.

PHARMAC estimates that the proposal would offer $1.5 million in savings per annum to those DHBs with Cardiac Catheterisation Laboratory (Cath Lab) services, based on current usage. The potential savings offered to individual DHBs will vary depending on the quantity and mix of devices purchased by each DHB.

Pricing for interventional cardiology products in the agreement, subject to any prior termination of the agreement, would not be increased before 1 April 2019.

The PHARMAC Agreement would supersede any existing DHB contracts with Boston for the devices listed in Schedule One of the Agreement. This would mean a device purchased by a DHB that is listed in the Agreement would have to be purchased at the Price as stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.

Interventional Cardiology devices not listed on the Pharmaceutical Schedule may still be purchased by DHBs, and DHBs would be under no obligation to purchase devices from Boston. 

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Friday 19 February 2016 to:

Jacquie Pillay
Devices Category Manager
PHARMAC                                                  
PO Box 10254
Wellington 6143

Email: jacquie.pillay@pharmac.govt.nz
Fax:      04 460 4995

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making decisions on these proposals.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request. 

Details of the proposal

PHARMAC has entered into a provisional agreement with Boston for a range of interventional cardiology products. The exact product range and pricing in this proposal has not been included in this consultation for brevity, however we are making it available to Procurement Departments at DHBs. Brand ranges include:

Promus Premier

Synergy

Mach 1

Runway

Convey

Impulse

Emerge

Maverick

Omega

Encore

Advantage

Rebel

NC Quantum Apex

NC Emerge

Starter

Luge

Flextome

Rotablator

FilterWire EZ

Kinetix

Kinetix Plus

Opticross

Atlantis Pro

Galaxy Sled

PT2

Guidezilla

 

 

 

 

If the agreement is approved by PHARMAC’s Board or its delegate, Boston’s range of interventional cardiology products would be listed in Part III of Section H of the Pharmaceutical Schedule, which contains products with national agreements that DHBs are able to purchase under. The agreement includes opportunities for savings through volume percentage commitment and commitment to purchase collective bundles of medical device ranges.

The agreement includes terms for education services to be provided by Boston to DHB personnel on appropriate use of its interventional cardiology products, which is to be provided at times as agreed with individual DHBs.